198 related articles for article (PubMed ID: 31575452)
21. GISTs with
Cao Z; Li J; Sun L; Xu Z; Ke Y; Shao B; Guo Y; Sun Y
Cancers (Basel); 2022 Dec; 15(1):. PubMed ID: 36612101
[TBL] [Abstract][Full Text] [Related]
22. Japanese Society of Medical Oncology/Japan Society of Clinical Oncology/Japanese Society of Pediatric Hematology/Oncology-led clinical recommendations on the diagnosis and use of tropomyosin receptor kinase inhibitors in adult and pediatric patients with neurotrophic receptor tyrosine kinase fusion-positive advanced solid tumors.
Naito Y; Mishima S; Akagi K; Hayashi N; Hirasawa A; Hishiki T; Igarashi A; Ikeda M; Kadowaki S; Kajiyama H; Kato M; Kenmotsu H; Kodera Y; Komine K; Koyama T; Maeda O; Miyachi M; Nishihara H; Nishiyama H; Ohga S; Okamoto W; Oki E; Ono S; Sanada M; Sekine I; Takano T; Tao K; Terashima K; Tsuchihara K; Yatabe Y; Yoshino T; Baba E
Int J Clin Oncol; 2023 Jul; 28(7):827-840. PubMed ID: 37212982
[TBL] [Abstract][Full Text] [Related]
23. Emerging Targeted Therapy for Tumors with
Kheder ES; Hong DS
Clin Cancer Res; 2018 Dec; 24(23):5807-5814. PubMed ID: 29986850
[TBL] [Abstract][Full Text] [Related]
24. [NTRK Fusions: A new way of treatment for gastro-intestinal tumor?].
Ouali K; Pellat A; Cohen R; Svrcek M; Penault-Llorca F; André T
Bull Cancer; 2020 Apr; 107(4):447-457. PubMed ID: 32067719
[TBL] [Abstract][Full Text] [Related]
25. Immunohistochemistry with a pan-TRK antibody distinguishes secretory carcinoma of the salivary gland from acinic cell carcinoma.
Hung YP; Jo VY; Hornick JL
Histopathology; 2019 Jul; 75(1):54-62. PubMed ID: 30801752
[TBL] [Abstract][Full Text] [Related]
26. NTRK Fusions, from the Diagnostic Algorithm to Innovative Treatment in the Era of Precision Medicine.
Zito Marino F; Pagliuca F; Ronchi A; Cozzolino I; Montella M; Berretta M; Errico ME; Donofrio V; Bianco R; Franco R
Int J Mol Sci; 2020 May; 21(10):. PubMed ID: 32466202
[TBL] [Abstract][Full Text] [Related]
27. Practical instructions for testing and targeted therapy in adult patients with solid tumours with NTRK gene fusion in common clinical practice.
Büchler T; Dundr P; Fínek J; Kiss I; Matěj R; Melichar B; Michal M; Petruželka L
Klin Onkol; 2020; 33(6):414-419. PubMed ID: 33685189
[TBL] [Abstract][Full Text] [Related]
28. NTRK gene fusions in melanoma: detection, prevalence and potential therapeutic implications.
Forschner A; Forchhammer S; Bonzheim I
J Dtsch Dermatol Ges; 2020 Dec; 18(12):1387-1392. PubMed ID: 32656925
[TBL] [Abstract][Full Text] [Related]
29. Validation and interpretation of Pan-TRK immunohistochemistry: a practical approach and challenges with interpretation.
Karakas C; Giampoli EJ; Love T; Hicks DG; Velez MJ
Diagn Pathol; 2024 Jan; 19(1):10. PubMed ID: 38200576
[TBL] [Abstract][Full Text] [Related]
30. Japan society of clinical oncology/Japanese society of medical oncology-led clinical recommendations on the diagnosis and use of tropomyosin receptor kinase inhibitors in adult and pediatric patients with neurotrophic receptor tyrosine kinase fusion-positive advanced solid tumors, cooperated by the Japanese society of pediatric hematology/oncology.
Naito Y; Mishima S; Akagi K; Igarashi A; Ikeda M; Okano S; Kato S; Takano T; Tsuchihara K; Terashima K; Nishihara H; Nishiyama H; Hiyama E; Hirasawa A; Hosoi H; Maeda O; Yatabe Y; Okamoto W; Ono S; Kajiyama H; Nagashima F; Hatanaka Y; Miyachi M; Kodera Y; Yoshino T; Taniguchi H
Int J Clin Oncol; 2020 Mar; 25(3):403-417. PubMed ID: 31974683
[TBL] [Abstract][Full Text] [Related]
31. Larotrectinib: First Global Approval.
Scott LJ
Drugs; 2019 Feb; 79(2):201-206. PubMed ID: 30635837
[TBL] [Abstract][Full Text] [Related]
32. The first case of gastric carcinoma with NTRK rearrangement: identification of a novel ATP1B-NTRK1 fusion.
Shinozaki-Ushiku A; Ishikawa S; Komura D; Seto Y; Aburatani H; Ushiku T
Gastric Cancer; 2020 Sep; 23(5):944-947. PubMed ID: 32189226
[TBL] [Abstract][Full Text] [Related]
33. [Novel targeted therapeutic option in oncology: tropomyosin receptor tyrosine kinase inhibitors].
Kiss E; Pápai Z
Orv Hetil; 2021 Aug; 162(34):1362-1369. PubMed ID: 34428172
[TBL] [Abstract][Full Text] [Related]
34. TRK Inhibitors: Clinical Development of Larotrectinib.
Bhangoo MS; Sigal D
Curr Oncol Rep; 2019 Feb; 21(2):14. PubMed ID: 30715603
[TBL] [Abstract][Full Text] [Related]
35. TRK inhibition in soft tissue sarcomas: A comprehensive review.
Assi T; Rassy E; Nassereddine H; Farhat F; Karak FE; Kattan J; Ghosn M
Semin Oncol; 2020 Feb; 47(1):73-84. PubMed ID: 32201016
[TBL] [Abstract][Full Text] [Related]
36. NTRK-rearranged mesenchymal tumours: diagnostic challenges, morphological patterns and proposed testing algorithm.
Wong DD; Vargas AC; Bonar F; Maclean F; Kattampallil J; Stewart C; Sulaiman B; Santos L; Gill AJ
Pathology; 2020 Jun; 52(4):401-409. PubMed ID: 32278476
[TBL] [Abstract][Full Text] [Related]
37. NTRK fusions are extremely rare in bone tumours.
Lam SW; Briaire-de Bruijn IH; van Wezel T; Cleven AHG; Hogendoorn PCW; Cleton-Jansen AM; Bovée JVMG
Histopathology; 2021 Nov; 79(5):880-885. PubMed ID: 34148257
[TBL] [Abstract][Full Text] [Related]
38. The Genomic and Proteomic Profiles of NTRK Genes and Trk Receptors in Liver Hepatocellular Carcinoma.
Wang H; Qi L; Zhong C; Fang X; Yuan Y
Clin Med Insights Oncol; 2023; 17():11795549231180840. PubMed ID: 37456611
[TBL] [Abstract][Full Text] [Related]
39.
Siozopoulou V; Smits E; De Winne K; Marcq E; Pauwels P
Diagnostics (Basel); 2021 Mar; 11(3):. PubMed ID: 33803146
[TBL] [Abstract][Full Text] [Related]
40. Evaluating larotrectinib for the treatment of advanced solid tumors harboring an NTRK gene fusion.
Filippi R; Depetris I; Satolli MA
Expert Opin Pharmacother; 2021 Apr; 22(6):677-684. PubMed ID: 33576301
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
